TrovaGene, Inc. (TROV)
-NasdaqCM 8.15 
0.97(13.51%) Oct 1, 4:00PM EDT
| Prev Close: | 7.18 |
|---|
| Open: | 7.35 |
|---|
| Bid: | 8.15 x 200 |
|---|
| Ask: | 8.40 x 500 |
|---|
| 1y Target Est: | 12.00 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | 11-Nov-13 |
|---|
| Day's Range: | 7.35 - 8.50 |
|---|
| 52wk Range: | 3.35 - 10.27 |
|---|
| Volume: | 721,450 |
|---|
| Avg Vol (3m): | 234,089 |
|---|
| Market Cap: | 153.59M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Nasdaq stocks posting largest percentage increasesAP(Tue, Oct 1)
- 4 Healthcare Stock Stories Making a Big Buzz Todayat Wall St. Cheat Sheet(Tue, Oct 1)
- First urine-based cancer mutation monitoring test available from TrovagenePR Newswire(Tue, Oct 1)
- You Could Double Your Money With This Future Medical SuperstarStreetAuthority Network(Wed, Sep 25)
- Trovagene Expands NPM Patent CoveragePR Newswire(Wed, Sep 25)
- 4 Healthcare Stock Stories for Weekend Investment Wellnessat Wall St. Cheat Sheet(Fri, Sep 6)
- TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Fri, Sep 6)
- Trovagene collaborates with USC in clinical study evaluating cancer monitoring technologyPR Newswire(Fri, Sep 6)
- Trovagene to Present at Two Healthcare ConferencesPR Newswire(Wed, Sep 4)
- Can Trovagene Be The Belle Of The Ball?at Seeking Alpha(Fri, Aug 30)
- TROVAGENE, INC. FinancialsEDGAR Online Financials(Wed, Aug 21)
- TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Wed, Aug 14)
- TROVAGENE, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 14)
- Trovagene, Inc. Announces Second Quarter 2013 EarningsPR Newswire(Wed, Aug 14)
- U.K. Asset Resolution Says Repaid Taxpayers 1.9 Billion Poundsat Bloomberg(Tue, Aug 6)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 249.26 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.84 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Trovagene Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines.
View More